What is the recommended dose of Xofluza (baloxavir marboxil) for a child ≥12 months old with acute influenza, based on weight and administered within 48 hours of symptom onset?

Xofluza Dosing for Children with Acute Influenza

For children ≥12 months old with acute influenza, Xofluza (baloxavir marboxil) is dosed as a single oral dose based on body weight: 2 mg/kg for children weighing <20 kg, 40 mg for those 20 to <80 kg, and 80 mg for those ≥80 kg, administered within 48 hours of symptom onset. 1

Age and Weight-Based Dosing Algorithm

Children 12 months to <12 years:

• Weight <20 kg: 2 mg/kg as a single oral dose 1, 2
• Weight 20 to <40 kg: 40 mg as a single oral dose 3
• Weight ≥40 kg: Follow adolescent/adult dosing below 3

Adolescents ≥12 years and Adults:

• Weight 40 to <80 kg: 40 mg as a single oral dose 3, 1
• Weight ≥80 kg: 80 mg as a single oral dose 3, 1

Critical Formulation Availability Issue

The oral suspension formulation required for children <20 kg was NOT available in the United States for the 2023-2024 influenza season, and availability for 2024-2025 remains uncertain. 3, 1 This severely limits the practical use of Xofluza in younger children who meet the age criteria but fall below the 20 kg weight threshold. 3

Administration Requirements

Food and Supplement Restrictions:

Baloxavir must NOT be taken with dairy products, calcium-fortified beverages, or supplements containing calcium, iron, magnesium, selenium, or zinc, as these dramatically reduce drug absorption and efficacy. 1 Patients should avoid these products for several hours before and after the dose. 1

Route of Administration:

• Can be given orally or via feeding tube without loss of effectiveness 1
• Administered as a single dose (major compliance advantage over 5-day oseltamivir regimen) 3

Timing of Treatment

Initiate treatment within 48 hours of symptom onset for optimal efficacy. 3, 1 This narrow therapeutic window is critical for achieving benefit. 3

Contraindications and Special Populations

Absolute Contraindications:

• Children <12 months old: Not FDA-approved for this age group 3, 1
• Severely immunocompromised patients: Should not receive baloxavir as monotherapy due to resistance risk 1
• Pregnant or breastfeeding women: Use is not advised 1

Renal and Hepatic Impairment:

• No dose adjustment required for mild-to-moderate hepatic or renal impairment 1, 4

Clinical Efficacy Considerations

Comparative Effectiveness:

• Similar time to symptom alleviation compared with oseltamivir in pediatric patients 3, 5
• Superior efficacy for influenza B infections compared with oseltamivir in randomized controlled trials 3
• More rapid viral load reduction than oseltamivir 3, 6

Pediatric-Specific Safety Signals:

In children <6 years, post-hoc analyses from Japanese studies showed symptom recurrence after day 4 in 54.5% and fever recurrence in 50% of treated children. 3, 1 This warrants close monitoring in younger pediatric patients, though the medication remains well-tolerated overall. 5, 2

Common Pitfalls to Avoid

1. Do not prescribe for children <20 kg if the oral suspension formulation is unavailable—only tablets are currently accessible in most U.S. settings 3, 1

2. Do not administer with dairy or polyvalent cation supplements—this is a critical drug interaction that nullifies efficacy 1

3. Do not delay treatment beyond 48 hours of symptom onset—efficacy diminishes significantly after this window 3, 1

4. Do not use as monotherapy in severely immunocompromised patients—resistance emergence is a documented concern 1

When to Choose Baloxavir Over Oseltamivir

Consider baloxavir as an alternative to oseltamivir when:

• Compliance with a 5-day, twice-daily regimen is a concern 3
• Poor tolerance of multiple-dose antiviral regimens 3
• Influenza B infection is confirmed or suspected 3
• Patient/family preference for single-dose therapy 3

However, oseltamivir remains the first-line agent for most pediatric patients, particularly those <5 years old, given the broader evidence base and lack of formulation barriers. 3